论文部分内容阅读
目的探讨黛力新结合瑞舒伐他汀治疗脑梗死后焦虑症的临床效果。方法选择2013年2月至2015年4月我院收治的卒中后合并焦虑抑郁者80例,按照数字随机法分为两组,每组各40例,所有患者均使用瑞舒伐他汀调节血脂,观察组使用黛力新,晨起口服1片,每次25 mg,每天早晚各1次,对所有患者随访3个月,比较两组干预前后HAMD和HAMA评分,并统计两组治疗期间发生的不良反应。结果干预前,两组HAMD和HAMA评分差异无统计学意义(P>0.05),干预后观察组HAMD和HAMA评分均低于干预前,且干预后观察组HAMD和HAMA评分低于对照组(P<0.05),观察组发生口干、失眠、皮肤荨麻疹及心动过速的比例均显著低于对照组(P<0.05)。结论黛力新对卒中后焦虑抑郁的改善效果,且具有副反应少,起效快,治疗依从性好等优点。
Objective To investigate the clinical effect of Deanxit and rosuvastatin on anxiety after cerebral infarction. Methods Eighty patients with post-stroke depression and anxiety who were admitted to our hospital from February 2013 to April 2015 were divided into two groups (n = 40) according to the random number method. All patients were treated with rosuvastatin to regulate blood lipids, The observation group using Deanxit, one morning oral dose of 25 mg, 1 time each morning and evening, all patients were followed up for 3 months, compared the two groups before and after intervention HAMD and HAMA scores, and statistics between the two groups occurred during treatment Adverse reactions. Results Before intervention, there was no significant difference in HAMD and HAMA scores between the two groups (P> 0.05). HAMD and HAMA scores of the observation group were lower than those before the intervention after intervention, and HAMD and HAMA scores of the observation group were lower than those of the control group <0.05). The rates of dry mouth, insomnia, skin urticaria and tachycardia in observation group were significantly lower than those in control group (P <0.05). Conclusions Deanin can improve the anxiety and depression after stroke, and has the advantages of less side effects, fast onset of action and good compliance of treatment.